Relevance, Reproducibility, and Reliability are Top Themes at Cell-Based Screening Conference | GenomeWeb

For several types of drug screening applications, cell-based assays are more relevant than biochemical assays, and in some cases essential. However, many pharmaceutical and biotech companies are still sometimes hesitant to incorporate them into screening programs because of the difficulty and cost of using appropriate cell lines, according to presentations at Cambridge Healthtech Institute’s 11th Annual Cell-Based Assays for High-Throughput Screening conference, held May 17-18 in Philadelphia.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.